HAUPTMENÜ
AWARDS
Forschergeist gefragt: 14. Novartis Oppenheim-Förderpreis für MS-Forschung ausgelobt
FernstudiumCheck Award: Deutschlands beliebteste Fernhochschule bleibt die SRH Fernhochschule
Vergabe der Wissenschaftspreise der Deutschen Hochdruckliga und der Deutschen Hypertoniestiftung
Den Patientenwillen auf der Intensivstation im Blick: Dr. Anna-Henrikje Seidlein…
Wissenschaft mit Auszeichnung: Herausragende Nachwuchsforscher auf der Jahrestagung der Deutschen…
VERANSTALTUNGEN
Wichtigster Kongress für Lungen- und Beatmungsmedizin ist erfolgreich gestartet
Virtuelle DGHO-Frühjahrstagungsreihe am 22.03. / 29.03. / 26.04.2023: Herausforderungen in…
Pneumologie-Kongress vom 29. März bis 1. April im Congress Center…
Die Hot Topics der Hirnforschung auf dem DGKN-Kongress für Klinische…
Deutscher Schmerz- und Palliativtag 2023 startet am 14.3.
DOC-CHECK LOGIN
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2012
London, UK (December 14, 2012) – This page provides an overview of the opinions adopted at the December 2012 meeting of the CHMP and other important outcomes. In the table below, readers can view the main opinions adopted at the meeting, as well as information on referral procedures.
To review the individual press releases, question-and-answer documents and other documents, please click on the links under ‘more information’. The Agency publishes a new page following the CHMP meeting each month.
Positive recommendations on new medicines
|
Name of medicine |
Adasuve |
|
International non-proprietary name (INN) |
loxapine |
|
Marketing-authorisation applicant |
Alexza UK Ltd |
|
Therapeutic indication |
Rapid control of agitation |
|
More information |
|
Name of medicine |
Perjeta |
|
INN |
pertuzumab |
|
Marketing-authorisation applicant |
Roche Registration Ltd |
|
Therapeutic indication |
Treatment of breast cancer |
|
More information |
|
Name of medicine |
Selincro |
|
INN |
nalmefene |
|
Marketing-authorisation applicant |
H.Lundbeck A/S |
|
Therapeutic indication |
Reduction of alcohol consumption in adult patients with alcohol dependence who have high drinking risk level, without physical withdrawal symptoms and who do not require immediate detoxification |
|
More information |
Negative recommendations on new medicines
|
Name of medicine |
Fanaptum |
|
INN |
iloperidone |
|
Marketing-authorisation applicant |
Vanda Pharmaceuticals Ltd |
|
Therapeutic indication |
Treatment of schizophrenia |
|
More information |
Questions and answers on the refusal of the marketing authorisation for Fanaptum |
|
Name of medicine |
Kynamro |
|
INN |
mipomersen |
|
Marketing-authorisation applicant |
Genzyme Europe B.V. |
|
Therapeutic indication |
Treatment of familial hypercholesterolaemia |
|
More information |
Questions and answers on the refusal of the marketing authorisation for Kynamro |
Positive recommendations on new therapeutic indications
|
Name of medicine |
Abilify |
|
INN |
aripiprazole |
|
Marketing-authorisation holder |
Otsuka Pharmaceutical Europe Ltd |
|
Therapeutic indication (changes in bold) |
Abilify is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. |
|
More information |
|
Name of medicine |
Ilaris |
|
INN |
canakinumab |
|
Marketing-authorisation holder |
Novartis Europharm Ltd |
|
Therapeutic indication (changes in bold) |
Treatment of cryopyrin-associated periodic syndromes (CAPS) in adults, adolescents and children aged 2 years and older with body weight of 7.5 kg or above, including: |
|
More information |
|
Name of medicine |
Ixiaro |
|
INN |
Japanese encephalitis vaccine (inactivated, adsorbed) |
|
Marketing-authorisation holder |
Intercell AG |
|
Therapeutic indication (changes in bold) |
Ixiaro is indicated for active immunization against Japanese encephalitis in adults, adolescents, children and infants aged 2 months and older. Ixiaro should be considered for use in individuals at risk of exposure through travel or in the course of their occupation. |
|
More information |
Recommendation for new contraindication
|
Name of medicine |
Pradaxa |
|
INN |
dabigatran etexilate |
|
Marketing-authorisation holder |
Boehringer Ingelheim International GmbH |
|
New contraindication |
Prosthetic heart valves requiring anticoagulant treatment |
|
More information |
Public-health recommendation on non-centrally authorised medicines
|
Name of medicine |
Tisseel, Tissucol, Artiss, Beriplast B |
|
INN |
fibrinogen-containing solutions for sealant |
|
More information |
|
Public-health recommendation on centrally and non-centrally authorised medicines
|
Name of medicine |
M-M-RVAXPRO, ProQuad, Zostavax, Amunovax, Priorix, Priorix Tetra, Provarivax, R.O.R. Vax, Rouvax, Trivivac, Varilrix, Varivax, and associated names |
|
INN |
monovalent and multivalent rubella, measles, mumps and varicella vaccine |
|
More information |
Re-examination of public-health recommendation
|
Name of medicine |
Fenofibrato Pensa, Fenofibrato Ranbaxy |
|
INN |
fenofibrate |
|
More information |
Withdrawals of applications
|
Name of medicine |
Combimarv |
|
INN |
insulin human |
|
More information |
Questions and answers on the withdrawal of the marketing authorisation application for Combimarv |
|
Name of medicine |
Isomarv medium |
|
INN |
insulin human |
|
More information |
|
Name of medicine |
Solumarv |
|
INN |
insulin human |
|
More information |
Questions and answers on the withdrawal of the marketing authorisation application for Solumarv |
|
Name of medicine |
Jenzyl |
|
INN |
ridaforolimus |
|
More information |
Questions and answers on on the withdrawal of the marketing authorisation application for Jenzyl |
Other updates
|
|
|
|
|
|
|
|
|
|
|
|
European Medicines Agency (EMA), 14.12.2012 (hB).